Our 2nd Annual EVIDENCE 360 Summit USA serves as a premier platform for U.S. healthcare stakeholders to examine the evolving role of Real-World Evidence (RWE) in shaping market access, pricing, and reimbursement strategies. As the demand grows for more cost-effective, outcomes-driven healthcare, EVIDENCE 360 USA brings together leading voices from pharma, biotech, payers, regulators, HTA bodies, and digital health innovators to address the most urgent access and value challenges across the U.S. market.
As the US market enters a new era defined by IRA drug price negotiations, increased CMS scrutiny, value-based care expansion, AI-enabled evidence generation, and growing demands for equity-driven outcomes, EVIDENCE 360 USA 2026 will focus on how companies can generate, translate, and operationalize RWE that truly moves payer and policy decisions.
This senior-level, two-day summit brings together pharma, biotech, payers, regulators, market access and HEOR leaders, RWE experts, and data innovators to explore how real-world evidence is actively reshaping pricing, reimbursement, and access decisions in the evolving US healthcare system.
Join peers and experts to explore how RWE is transforming evidence generation, payer engagement, and regulatory strategy—empowering better, faster, and smarter healthcare decisions.
